EFFECTS OF PROBUCOL ON PLASMA-LIPOPROTEIN SUBFRACTIONS AND ACTIVITIES OF LIPOPROTEIN-LIPASE AND HEPATIC TRIGLYCERIDE LIPASE

被引：20

作者：

HOMMA, Y ^{[1
]}

MORIGUCHI, EH ^{[1
]}

SAKANE, H ^{[1
]}

OZAWA, H ^{[1
]}

NAKAMURA, H ^{[1
]}

GOTO, Y ^{[1
]}

机构：

[1] NATL DEF MED COLL, DEPT INTERNAL MED 1, TOKOROZAWA, SAITAMA 359, JAPAN

来源：

ATHEROSCLEROSIS | 1991年 / 88卷 / 2-3期

关键词：

PROBUCOL; LIPOPROTEIN SUBFRACTION; LIPOPROTEIN LIPASE; HEPATIC TRIGLYCERIDE LIPASE; HYPERLIPOPROTEINEMIA;

D O I：

10.1016/0021-9150(91)90079-I

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The effects of 12 weeks treatment with probucol on plasma lipoprotein subfraction levels and on LPL and HTGL activities were investigated. Plasma VLDL-C, VLDL-TG, VLDL-apo B levels were not changed. Probucol significantly reduced plasma IDL-C and IDL-apo B levels by 26.7% and 23.8%, respectively. Plasma cholesterol and apo B levels of large light LDL (LDL1) were decreased significantly by 27.8% and 23.2% by probucol treatment. Plasma cholesterol and apo B levels of small heavy LDL (LDL2) remained unchanged. Probucol markedly reduced plasma HDL2 levels. The reduction rates of plasma TC, TG and apo A-I levels of HDL2 were 43.0%, 43.6% and 47.0%. Probucol significantly decreased HDL3-C and HDL3-apo A-I levels by 18.0% and 19.2%. LPL activities in the post-heparin plasma were decreased significantly from 2.53 +/- 0.71-mu-mol free fatty acids (FFA)/ml/h to 1.71 +/- 0.71-mu-mol FFA/ml/h by probucol while HTGL activities remained unchanged. We conclude that probucol suppresses LPL activity and decreases plasma IDL, LDL, and HDL2 levels due to disturbances of VLDL conversion to LDL1 via IDL and of HDL3 conversion to HDL2.

引用

页码：175 / 181

页数：7

共 40 条

[1] ATMEH RF, 1983, J LIPID RES, V24, P588
[2] AUGUSTIN J, 1978, J BIOL CHEM, V253, P2912
[3] AUSTIN M A, 1988, Journal of the American Medical Association, V260, P1917, DOI 10.1001/jama.260.13.1917
[4] LARGE BUOYANT LDL-LIKE PARTICLES IN HEPATIC LIPASE DEFICIENCY
AUWERX, JH
MARZETTA, CA
HOKANSON, JE
BRUNZELL, JD
[J]. ARTERIOSCLEROSIS, 1989, 9 (03): : 319 - 325
[5] PROBUCOL TREATMENT IN HYPERCHOLESTEROLEMIC PATIENTS - EFFECTS ON LIPOPROTEIN COMPOSITION, HDL PARTICLE-SIZE, AND CHOLESTERYL ESTER TRANSFER
BAGDADE, JD
KAUFMAN, D
RITTER, MC
SUBBAIAH, PV
[J]. ATHEROSCLEROSIS, 1990, 84 (2-3) : 145 - 154
[6] EFFECTS OF PROBUCOL ON THE COMPOSITION AND INVITRO CATABOLISM OF LDL IN TYPE-IIA HYPERCHOLESTEROLEMIA
BAUDET, MF
ESTEVA, O
DACHET, C
JACOTOT, B
[J]. ATHEROSCLEROSIS, 1986, 62 (01) : 65 - 71
[7] ANTIATHEROGENIC EFFECT OF PROBUCOL UNRELATED TO ITS HYPOCHOLESTEROLEMIC EFFECT - EVIDENCE THAT ANTIOXIDANTS INVIVO CAN SELECTIVELY INHIBIT LOW-DENSITY-LIPOPROTEIN DEGRADATION IN MACROPHAGE-RICH FATTY STREAKS AND SLOW THE PROGRESSION OF ATHEROSCLEROSIS IN THE WATANABE HERITABLE HYPERLIPIDEMIC RABBIT
CAREW, TE
SCHWENKE, DC
STEINBERG, D
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (21) : 7725 - 7729
[8] THE EFFECTS OF PROBUCOL ON PLASMA-LIPOPROTEINS IN POLYGENIC AND FAMILIAL HYPERCHOLESTEROLEMIA
CORTESE, C
MARENAH, CB
MILLER, NE
LEWIS, B
[J]. ATHEROSCLEROSIS, 1982, 44 (03) : 319 - 325
[9] CROUSE JR, 1985, J LIPID RES, V26, P566
[10] DECKELBAUM RJ, 1982, J BIOL CHEM, V257, P6509

← 1 2 3 4 →